9,779 Shares in Illumina, Inc. (NASDAQ:ILMN) Acquired by Capital Group Investment Management PTE. LTD.

Capital Group Investment Management PTE. LTD. acquired a new stake in Illumina, Inc. (NASDAQ:ILMN) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 9,779 shares of the life sciences company’s stock, valued at approximately $1,307,000.

Several other large investors have also recently added to or reduced their stakes in ILMN. Capital International Sarl bought a new stake in shares of Illumina in the fourth quarter valued at about $9,174,000. CANADA LIFE ASSURANCE Co raised its stake in Illumina by 5.1% in the 4th quarter. CANADA LIFE ASSURANCE Co now owns 279,836 shares of the life sciences company’s stock worth $37,382,000 after purchasing an additional 13,563 shares in the last quarter. Farringdon Capital Ltd. bought a new stake in Illumina in the 4th quarter valued at about $206,000. Zacks Investment Management grew its position in shares of Illumina by 3.5% during the 4th quarter. Zacks Investment Management now owns 23,210 shares of the life sciences company’s stock worth $3,102,000 after purchasing an additional 786 shares in the last quarter. Finally, Jump Financial LLC increased its holdings in shares of Illumina by 260.0% during the fourth quarter. Jump Financial LLC now owns 7,865 shares of the life sciences company’s stock worth $1,051,000 after purchasing an additional 5,680 shares during the period. Institutional investors own 89.42% of the company’s stock.

Illumina Trading Down 3.2 %

NASDAQ ILMN opened at $71.21 on Friday. The company has a market cap of $11.28 billion, a price-to-earnings ratio of -9.27, a price-to-earnings-growth ratio of 1.60 and a beta of 1.38. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $156.66. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The business’s fifty day moving average is $85.20 and its 200 day moving average is $120.80.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. As a group, sell-side analysts expect that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on ILMN shares. Guggenheim cut their price target on Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Barclays reduced their target price on Illumina from $100.00 to $77.00 and set an “underweight” rating on the stock in a report on Thursday, April 10th. Canaccord Genuity Group dropped their price target on Illumina from $135.00 to $115.00 and set a “hold” rating for the company in a research note on Tuesday, March 11th. Morgan Stanley cut their price objective on shares of Illumina from $150.00 to $136.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 11th. Finally, Hsbc Global Res lowered shares of Illumina from a “strong-buy” rating to a “hold” rating in a report on Friday, February 28th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Illumina presently has a consensus rating of “Moderate Buy” and an average target price of $138.70.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.